Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells 1,000 Shares of Stock

Key Points

• Krista Davis, Senior Vice President of ANI Pharmaceuticals, sold 1,000 shares of the company's stock for a total of $98,040, reducing her ownership by 1.63% to 60,186 shares.
• ANI Pharmaceuticals reported a 53.2% increase in revenue year-over-year, reaching $211.37 million, and surpassed analysts' earnings expectations by reporting $1.80 earnings per share.
• A number of brokerages have recently upgraded ANI Pharmaceuticals' stock rating, with Zacks Research and Wall Street Zen issuing a "strong-buy" rating, reflecting positive investor sentiment.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Krista Davis sold 1,000 shares of the business's stock in a transaction that occurred on Friday, September 19th. The shares were sold at an average price of $98.04, for a total value of $98,040.00. Following the transaction, the senior vice president owned 60,186 shares of the company's stock, valued at $5,900,635.44. This trade represents a 1.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Krista Davis also recently made the following trade(s):

• On Friday, August 22nd, Krista Davis sold 1,763 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $91.10, for a total transaction of $160,609.30.

ANI Pharmaceuticals Stock Down 1.0%

NASDAQ:ANIP traded down $0.93 during trading hours on Tuesday, reaching $95.00. The company's stock had a trading volume of 138,680 shares, compared to its average volume of 374,236. The stock has a 50 day moving average price of $83.32 and a two-hundred day moving average price of $71.38. The company has a market capitalization of $2.06 billion, a P/E ratio of -123.38 and a beta of 0.63. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The business had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The business's quarterly revenue was up 53.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 earnings per share. Equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co boosted its holdings in ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company's stock valued at $1,267,000 after purchasing an additional 198 shares during the last quarter. Hohimer Wealth Management LLC boosted its holdings in ANI Pharmaceuticals by 5.2% in the first quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock valued at $334,000 after purchasing an additional 247 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in ANI Pharmaceuticals by 2.6% in the second quarter. Thrivent Financial for Lutherans now owns 12,511 shares of the specialty pharmaceutical company's stock valued at $816,000 after purchasing an additional 321 shares during the last quarter. Legal & General Group Plc boosted its holdings in ANI Pharmaceuticals by 0.8% in the second quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company's stock valued at $3,048,000 after purchasing an additional 351 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in ANI Pharmaceuticals by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock valued at $582,000 after purchasing an additional 364 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ANIP shares. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Truist Financial upped their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, August 11th. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a "buy" rating in a report on Monday, September 8th. Piper Sandler reissued an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, HC Wainwright boosted their price objective on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a "buy" rating in a report on Wednesday, September 17th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals currently has an average rating of "Buy" and an average price target of $93.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.